What is Glutamic Acid Decarboxylase (GAD)?
Glutamic acid decarboxylase (GAD) is an enzyme that catalyzes the conversion of glutamic acid (glutamate) into gamma-aminobutyric acid (GABA), the primary inhibitory neurotransmitter in the central nervous system. 1
Biochemical Function
GAD exists in two main isoforms—GAD65 and GAD67—which are encoded by separate genes and have distinct regulatory mechanisms 2, 3. Both isoforms are pyridoxal phosphate (PLP)-dependent enzymes that perform the same catalytic function: the alpha-decarboxylation of glutamate to produce GABA and CO2 4.
Tissue Distribution and Expression
GAD is widely expressed in two primary locations:
- Central nervous system: Found in inhibitory neurons throughout the brain, localized to axon terminals, soma, and dendrites 5, 2
- Pancreatic β-cells: Where GABA produced by GAD plays a role in regulating insulin secretion 1
Clinical Significance in Diabetes
In the context of diabetes, GAD is most clinically relevant as an autoimmune marker. Autoantibodies to GAD (particularly GAD65) are one of the key islet autoantibodies used for:
- Screening for presymptomatic type 1 diabetes alongside antibodies to insulin, islet antigen 2 (IA-2), and zinc transporter 8 (ZnT8) 6, 7
- Classifying diabetes type in adults with overlapping phenotypic features (younger age at diagnosis, unintentional weight loss, ketoacidosis, rapid progression to insulin) 6
- Identifying latent autoimmune diabetes of adults (LADA), where approximately 5-10% of White adults presenting with type 2 diabetes phenotype have GAD antibodies that predict insulin dependency 8
Diagnostic Application
The presence of multiple islet autoantibodies including anti-GAD defines Stage 1 type 1 diabetes (with normoglycemia) and carries a 44% 5-year risk of developing symptomatic diabetes 6, 7. When GAD antibodies are detected alongside other islet autoantibodies and dysglycemia (Stage 2), the risk increases to 60% by 2 years 6, 7.
Clinical Significance in Neurological Disorders
GAD antibodies are also associated with GAD antibody-spectrum disorders (GAD-SD), which include 1, 9:
- Stiff-person syndrome (SPS)
- Cerebellar ataxia
- Limbic encephalitis
- Drug-resistant epilepsy
- Cognitive impairment
These neurological manifestations may occur independently or alongside type 1 diabetes, as GAD is expressed in both pancreatic β-cells and the central nervous system 1, 10.
Important Testing Considerations
GAD autoantibody testing should only be performed in accredited laboratories with established quality control programs 8. The clinical utility differs by context:
- Screening: Recommended for first-degree relatives of type 1 diabetes patients or in research settings 8, 11
- Diagnosis: Useful for classifying diabetes type in ambiguous presentations 6
- Monitoring: No role for repeated GAD antibody measurement in established type 1 diabetes outside research protocols 8